Kathleen E Squires

Summary

Affiliation: Thomas Jefferson University
Country: USA

Publications

  1. pmc Insights on GRACE (Gender, Race, And Clinical Experience) from the patient's perspective: GRACE participant survey
    Kathleen Squires
    Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA 19107, USA
    AIDS Patient Care STDS 27:352-62. 2013
  2. doi request reprint Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study
    Kathleen E Squires
    Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA 19107, USA
    AIDS Res Hum Retroviruses 29:859-70. 2013
  3. doi request reprint ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine
    Kathleen E Squires
    Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
    HIV Clin Trials 13:233-44. 2012
  4. pmc Gender-sensitive reporting in medical research
    Shirin Heidari
    International AIDS Society, Geneva, Switzerland
    J Int AIDS Soc 15:11. 2012
  5. doi request reprint Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients
    Kathleen E Squires
    Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    HIV Clin Trials 11:69-79. 2010
  6. ncbi request reprint Gender differences in the diagnosis and treatment of HIV
    Kathleen E Squires
    Division of Infectious Diseases, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Gend Med 4:294-307. 2007
  7. doi request reprint Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients
    Kathleen E Squires
    Division of Infectious Diseases, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    AIDS 24:2019-27. 2010
  8. pmc Health needs of HIV-infected women in the United States: insights from the women living positive survey
    Kathleen E Squires
    Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    AIDS Patient Care STDS 25:279-85. 2011
  9. pmc Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study
    Kathleen E Squires
    Jefferson Medical College of Thomas Jefferson University, 211 South 9th Street, Philadelphia, PA 19107, USA
    J Antimicrob Chemother 66:363-70. 2011
  10. doi request reprint Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus
    Jason J Schafer
    Jefferson School of Pharmacy, Thomas Jefferson University, Philadelphia, Pennsylvania 19107 5233, USA
    Pharmacotherapy 30:1072-83. 2010

Detail Information

Publications36

  1. pmc Insights on GRACE (Gender, Race, And Clinical Experience) from the patient's perspective: GRACE participant survey
    Kathleen Squires
    Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA 19107, USA
    AIDS Patient Care STDS 27:352-62. 2013
    ..Patients with these characteristics may be at risk of poor study outcomes and may benefit from additional adherence and retention strategies in future studies and routine clinical care...
  2. doi request reprint Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study
    Kathleen E Squires
    Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA 19107, USA
    AIDS Res Hum Retroviruses 29:859-70. 2013
    ..After 48 weeks of treatment in a diverse cohort of HIV-infected patients, raltegravir was generally safe and well tolerated with potent efficacy regardless of gender or race...
  3. doi request reprint ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine
    Kathleen E Squires
    Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
    HIV Clin Trials 13:233-44. 2012
    ..Non-inferiority of the unboosted regimen was demonstrated at week 84. In this optional extension phase, virologic suppression and adverse events were assessed through week 144...
  4. pmc Gender-sensitive reporting in medical research
    Shirin Heidari
    International AIDS Society, Geneva, Switzerland
    J Int AIDS Soc 15:11. 2012
    ..Journal editors are also promoters of ethical research and adequate standards of reporting, and requirements for inclusion of gender analyses should be integrated into editorial policies as a matter of urgency...
  5. doi request reprint Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients
    Kathleen E Squires
    Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    HIV Clin Trials 11:69-79. 2010
    ..The ARIES study assessed safety and efficacy of an induction regimen with atazanavir/ritonavir (ATV/RTV) + abacavir/lamivudine (ABC/3TC) followed by simplification to ATV + ABC/3TC in antiretroviral-naïve patients...
  6. ncbi request reprint Gender differences in the diagnosis and treatment of HIV
    Kathleen E Squires
    Division of Infectious Diseases, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Gend Med 4:294-307. 2007
    ..Timing and choice of treatment are affected by the pharmacokinetics of antiretroviral drugs and the long-term complications of treatment, both of which may be different for men and women with HIV infection...
  7. doi request reprint Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients
    Kathleen E Squires
    Division of Infectious Diseases, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    AIDS 24:2019-27. 2010
    ....
  8. pmc Health needs of HIV-infected women in the United States: insights from the women living positive survey
    Kathleen E Squires
    Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    AIDS Patient Care STDS 25:279-85. 2011
    ..These data highlight a need for U.S. health care providers to incorporate discussion of gender-specific issues, including preconception and reproductive counseling, into management strategies for HIV-infected women...
  9. pmc Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study
    Kathleen E Squires
    Jefferson Medical College of Thomas Jefferson University, 211 South 9th Street, Philadelphia, PA 19107, USA
    J Antimicrob Chemother 66:363-70. 2011
    ..The trial is registered with ClinicalTrials.gov, number NCT00272779...
  10. doi request reprint Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus
    Jason J Schafer
    Jefferson School of Pharmacy, Thomas Jefferson University, Philadelphia, Pennsylvania 19107 5233, USA
    Pharmacotherapy 30:1072-83. 2010
    ..Studies are also necessary to definitively identify the contributions of both HIV infection and individual antiretroviral agents on the development of cardiovascular disease...
  11. pmc A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen
    Scott M Hammer
    Division of Infectious Diseases, Columbia University, New York, New York 10032, USA
    HIV Clin Trials 11:312-24. 2010
    ..The objective of AIDS Clinical Trials Group Study 372A was to determine whether the intensification strategy of adding abacavir to an effective indinavir-dual nucleoside regimen would delay the time to virologic failure...
  12. doi request reprint Bone health and human immunodeficiency virus infection
    Jason J Schafer
    Department of Pharmacy Practice, Jefferson School of Pharmacy, Thomas Jefferson University, Philadelphia, Pennsylvania 19107 5233, USA
    Pharmacotherapy 33:665-82. 2013
    ..Further study is necessary to definitively determine the approach to evaluating bone health and managing low bone mineral density and vitamin D deficiency in patients with HIV infection...
  13. doi request reprint Integrase inhibitors: a novel class of antiretroviral agents
    Jason J Schafer
    Jefferson School of Pharmacy, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Ann Pharmacother 44:145-56. 2010
    ..To review the pharmacology, efficacy, safety, and resistance profiles of the integrase inhibitors raltegravir and elvitegravir...
  14. doi request reprint Cobicistat: a new boost for the treatment of human immunodeficiency virus infection
    Bhavik M Shah
    Department of Pharmacy Practice, Jefferson School of Pharmacy, Thomas Jefferson University, Philadelphia, Pennsylvania
    Pharmacotherapy 33:1107-16. 2013
    ..Cobicistat is well tolerated and may become a preferred booster for antiretroviral regimens, as it can be coformulated with several agents to create simpler regimens. ..
  15. doi request reprint Prevalence of obstructive lung disease in HIV population: a cross sectional study
    Amyn Hirani
    Division of Pulmonary and Critical Care Medicine, Thomas Jefferson University, Philadelphia, PA, USA
    Respir Med 105:1655-61. 2011
    ..Observational studies have suggested an association between HIV infection and emphysema...
  16. ncbi request reprint Women and HIV: a population at risk
    Kathleen E Squires
    Division of Infectious Diseases, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Res Initiat Treat Action 12:18-20. 2007
  17. ncbi request reprint Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248)
    Mary A Vogler
    New York University Medical Center, New York, NY 10016, USA
    J Acquir Immune Defic Syndr 36:576-87. 2004
    ..Approaches to preserve or enhance immune function in HIV-1 infection are needed...
  18. ncbi request reprint Treating HIV infection and AIDS in women
    Kathleen E Squires
    University of Southern California USC Keck School of Medicine, Los Angeles, California, USA
    AIDS Read 13:228-34, 239-40. 2003
  19. ncbi request reprint Gender-specific considerations in the antiretroviral management of HIV-infected women
    Rebecca A Clark
    HIV Outpatient Program, New Orleans, LA 70112, USA
    Expert Rev Anti Infect Ther 3:213-27. 2005
    ..Further investigation into gender-related issues, including sex-associated antiretroviral toxicities, unique pharmacokinetic profiles and optimal antiretroviral management during pregnancy is needed...
  20. ncbi request reprint Once-daily antiretroviral therapies for HIV infection: Consensus Statement of an Advisory Committee of the International Association of Physicians in AIDS Care
    Calvin Cohen
    CRI New England, 23 Miner Street, Boston, Massachusetts 02215 3318, USA
    J Int Assoc Physicians AIDS Care (Chic) 1:141-5. 2002
    ..The opinions expressed in this Consensus Statement represent only those of the Advisory Committee...
  21. ncbi request reprint Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial
    Roy M Gulick
    Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY, USA
    JAMA 296:769-81. 2006
    ..Three-drug antiretroviral regimens are standard of care for initial treatment of human immunodeficiency virus 1 (HIV-1) infection, but a 4-drug regimen could improve antiretroviral activity and be more effective than a 3-drug regimen...
  22. ncbi request reprint Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression
    Roy M Gulick
    Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
    AIDS 21:813-23. 2007
    ..To compare a quadruple-nucleoside with an efavirenz-containing regimen for treatment of HIV-1 infection...
  23. pmc Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity
    Sharon A Riddler
    University of Pittsburgh, Pennsylvania, USA
    Antimicrob Agents Chemother 46:3877-82. 2002
    ..The combination of IDV and NFV was generally well tolerated and resulted in sustained virologic suppression with 45% of the subjects having an HIV-1 RNA level in plasma of <400 copies/ml at week 72 (intent-to-treat)...
  24. ncbi request reprint A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: correlations with CD4 cell count and plasma HIV-1 RNA level
    Patty W Wright
    Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294 0006, USA
    Clin Infect Dis 36:207-11. 2003
    ..Positive HSV-2 culture results occurred more frequently for samples obtained from patients with higher plasma HIV-1 RNA levels (P=.019) and lower CD4 cell counts (P<.001)...
  25. ncbi request reprint Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients
    Gail Skowron
    Roger Williams Medical Center, Providence, Rhode Island 02908, USA
    J Infect Dis 186:1028-33. 2002
    ....
  26. ncbi request reprint Current management challenges in HIV: antiretroviral resistance
    Daniel R Kuritzkes
    Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts, USA
    AIDS Read 13:133-5, 138-42. 2003
    ..However, there is a need for additional trials to better define the role resistance testing may play in developing management approaches to mitigate or minimize emergence of resistant HIV...
  27. pmc Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects
    Robert Dicenzo
    University at Buffalo, Buffalo, New York, USA
    Antimicrob Agents Chemother 47:1929-35. 2003
    ..Abacavir did not influence the pharmacokinetics or exposure parameters of either indinavir or efavirenz. The levels of efavirenz exposure were similar in subjects receiving efavirenz q12h or q24h...
  28. ncbi request reprint Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women
    Raphael P Viscidi
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Infect Dis 187:194-205. 2003
    ..Despite the higher prevalence of HPV infection in this group, most HIV-positive women are able to control HPV-16 replication at the cervix, and reactivation, if it occurs, is not very common...
  29. ncbi request reprint Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s
    Daniel R Kuritzkes
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, Cambridge, MA 02139, USA
    J Infect Dis 195:1169-76. 2007
    ..We sought to compare clearance rates of plasma human immunodeficiency virus type 1 (HIV-1) RNA in men and women starting triple-nucleoside-based versus efavirenz (EFV)-based regimens...
  30. ncbi request reprint Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection
    Roy M Gulick
    Weill Medical College of Cornell University, New York, USA
    N Engl J Med 350:1850-61. 2004
    ....
  31. ncbi request reprint Incidence and risk factors for sexually transmitted infections among women in an Alabama HIV clinic
    Cheryl Ann Monteiro
    Department of Medicine, The University of Alabama at Birmingham, Alabama 35294, USA
    AIDS Res Hum Retroviruses 20:577-83. 2004
    ..99 (1.28, 3.08), and a higher CD4+ T cell count, RR = 1.15 (1.0028, 1.3115) for 100 cells. Interventions to prevent curable STI in HIV-infected women are warranted in primary care settings...
  32. ncbi request reprint Editorial comment: HIV-infected women require a range of specialized services
    Kathleen E Squires
    AIDS Read 15:426. 2005
  33. doi request reprint The costs of HIV antiretroviral therapy adherence programs and impact on health care utilization
    Stephanie L Sansom
    US Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    AIDS Patient Care STDS 22:131-8. 2008
    ..IACM was associated with a significant decrease in hospital days compared to SOC and was cost saving when program costs were compared to savings in health care utilization...
  34. ncbi request reprint Editorial comment: women and HIV--a population at risk
    Kathleen E Squires
    AIDS Read 16:374-5. 2006
  35. ncbi request reprint Factors influencing the acceptance of changes in antiretroviral therapy among HIV-1-infected patients
    Rafael E Campo
    University of Miami School of Medicine, Miami, Florida 33136, USA
    AIDS Patient Care STDS 21:329-38. 2007
    ..ART acceptance rates among Hispanic patients were lower...
  36. ncbi request reprint Comparative analysis of commercial assays for the detection and quantification of Human Immunodeficiency Virus Type 1 (HIV-1) RNA in plasma from patients infected with HIV-1 subtype C
    Craig J Hoesley
    Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL, 35294, USA
    Clin Infect Dis 35:323-5. 2002
    ..Each assay detected plasma HIV-1 RNA, but they do not all measure statistically similar quantities of plasma HIV-1 RNA...